Kabuki syndrome: 2026 so far

Shifted from occasional concern to a genotype-linked pattern.

In the months covered, the clearest management-related update was a more detailed picture of low blood sugar in Kabuki syndrome linked to congenital hyperinsulinism (too much insulin made from birth). Reports also noted that in a smaller subset, low blood sugar could persist beyond the newborn period. A small, single-center retrospective experience suggested that persistent or recurrent episodes clustered in children with truncating KMT2D variants and were not seen in those with missense variants in that cohort. When episodes persisted, treatment with diazoxide was described, and one patient also needed octreotide. This connects symptoms to a treatable mechanism in at least some children, which can help explain why low blood sugar may come back and what treatments were used in the reported cases.

Research covered in: February 2026

Case reports expanded the range of high-complexity situations.

From January to July, most management updates were single-patient reports. These reports expand what has been documented, but they do not show what is typical. One report described a prolonged spine-surgery course after fusion, with multiple staged revisions and a postoperative Staphylococcus aureus infection, and later follow-up noting stable alignment and improved function (one teenager). Separate single reports described bilateral hip dysplasia reconstruction with improved imaging at about 1 year (one child), complex aortic disease treated surgically with good short-term recovery (one child), and a newborn with a KMT2D variant (the gene that causes Kabuki syndrome) who was diagnosed with Hirschsprung disease (a condition where part of the bowel lacks nerve cells) after birth and needed major bowel surgery (reported in a prenatal case report). Taken together, these examples show the kinds of specialized procedures and follow-up that have been described in individual situations, without telling how often they happen.

Research covered in: January 2026, February 2026, March 2026, July 2026

One cohort added longer-term outcome detail by anatomy.

In September, a single-center hospital cohort added more specific outcome information for congenital heart disease in Kabuki syndrome. It emphasized that risk differed based on the exact heart anatomy. In that cohort, in-hospital deaths were mainly reported in children with single-ventricle physiology who underwent complex surgery. No deaths were reported in the group managed without surgery, and the study did not report late deaths during follow-up. This does not add a new treatment, but it supports the idea that heart findings can range from non-surgical management to complex operations with higher early hospital risk, so prognosis discussions may depend heavily on an individual child's heart structure and the complexity of the planned surgery.

Research covered in: September 2026

New lab classifier plus case reports highlighted limits of earlier tests.

So far in 2026, the largest diagnostic step was a blood DNA methylation episignature (a pattern of chemical tags on DNA used for classification). This episignature separated Kabuki syndrome type 1 (KMT2D-related) from controls with very high accuracy in validation testing (reported sensitivity 97% and specificity 100%), and it also classified some KS2 (KDM6A-related) cases. Alongside this, a few single case reports showed that earlier testing, including a normal chromosome microarray (a test that looks for missing or extra DNA pieces), can miss Kabuki syndrome. In those reports, trio/whole-exome sequencing (a test that reads most protein-coding genes, often in child and parents) identified KDM6A or KMT2D variants in prenatal settings where ultrasound findings were nonspecific. One prenatal report also showed that more than one genetic diagnosis can be present (Kabuki syndrome plus primary carnitine deficiency due to SLC22A5). This points to clearer ways to resolve uncertain genetic findings in some situations, while also showing that broad testing can sometimes uncover more than one explanation for a complex presentation.

Research covered in: March 2026, May 2026, July 2026

Outcome measures became more defined for KS1 and KS2.

In August, a small study in adolescents and adults with molecularly confirmed KS1 tested a Kabuki Syndrome Cognitive Assessment Battery twice on consecutive days. It found several visuospatial and attention tasks had high repeatability, with visuospatial skills (understanding and working with visual information and space) the most consistently difficult area. One task showed a floor effect (scores were already very low, limiting change tracking) that limited its usefulness for tracking change in some participants. In September, caregiver questionnaires in a separate sample described peer relationship difficulties as common. They also reported autism diagnoses or autism-related characteristics more often in KS2 than KS1, with different patterns of challenges by subtype in that report. These studies mainly support more consistent, subtype-aware ways to describe and measure day-to-day function in research, which may shape how changes are tracked in future studies.

Research covered in: August 2026, September 2026